Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Edgar G, Rizzatti"'
Autor:
Adrian Wiestner, Wyndham H. Wilson, Yihong Ye, Kieron Dunleavy, Megan M. Tweito, Therese White, Nalini Raghavachari, Peter J. Munson, Qiuyan Wang, Delong Liu, Patricia Pérez-Galán, Edgar G. Rizzatti, Marc A. Weniger
Purpose: Proteasome inhibition disrupts protein homeostasis and induces apoptosis. Up to 50% of patients with relapsed mantle cell lymphoma (MCL) respond to bortezomib. We used gene expression profiling to investigate the connection between proteasom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d39e2af88423ca501ed975864291e05f
https://doi.org/10.1158/1078-0432.c.6519399.v1
https://doi.org/10.1158/1078-0432.c.6519399.v1
Autor:
Adrian Wiestner, Wyndham H. Wilson, Yihong Ye, Kieron Dunleavy, Megan M. Tweito, Therese White, Nalini Raghavachari, Peter J. Munson, Qiuyan Wang, Delong Liu, Patricia Pérez-Galán, Edgar G. Rizzatti, Marc A. Weniger
PDF file - 73K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::335e342057e25a6dd1ae13abd4b472a2
https://doi.org/10.1158/1078-0432.22442730.v1
https://doi.org/10.1158/1078-0432.22442730.v1
Autor:
Kieron Dunleavy, Wyndham H. Wilson, Delong Liu, Yihong Ye, Adrian Wiestner, Edgar G. Rizzatti, Nalini Raghavachari, Therese White, Megan M. Tweito, Qiuyan Wang, Peter J. Munson, Marc A. Weniger, Patricia Pérez-Galán
Publikováno v:
Clinical Cancer Research. 17:5101-5112
Purpose: Proteasome inhibition disrupts protein homeostasis and induces apoptosis. Up to 50% of patients with relapsed mantle cell lymphoma (MCL) respond to bortezomib. We used gene expression profiling to investigate the connection between proteasom
Autor:
Adrian Wiestner, Federica Gibellini, Marc A. Weniger, Helena Mora-Jensen, Masanori Daibata, Raymond Lai, Elinor Lee, Edgar G. Rizzatti
Publikováno v:
Leukemia & Lymphoma. 49:798-808
Bortezomib is more active against mantle cell lymphoma (MCL) than against most other lymphoma subtypes. Nevertheless, up to half of patients with MCL have bortezomib resistant disease. Factors contributing to intrinsic resistance to bortezomib have n
Autor:
Adrian Wiestner, Edgar G. Rizzatti
Publikováno v:
Drug Discovery Today: Disease Mechanisms. 3:507-514
Gene expression profiling is transforming the classification of hematologic malignancies by defining disease entities based on shared genetic lesions. Surprising findings have come from these studies. First, gene expression profiles in samples at dia
Autor:
Flávia Leite Souza Santos, Adriana I. Dore, Ana Sílvia G. Lima, Aglair B. Garcia, Marco A. Zago, Edgar G. Rizzatti, Jorge Elias Jr, Roberto Passetto Falcão, Eduardo Magalhães Rego
Publikováno v:
Revista da Associação Médica Brasileira, Vol 50, Iss 3, Pp 286-292 (2004)
OBJETIVO: A leucemia promielocítica aguda (LPA) apresenta uma boa resposta ao tratamento com o ácido all trans retinóico (ATRA). Entretanto, alguns pacientes desenvolvem uma complicação grave chamada síndrome do ácido retinóico (SAR). O objet
Autor:
Alex F, Sandes, Maria, de Lourdes Chauffaille, Cláudia Regina M C, Oliveira, Yumi, Maekawa, Nair, Tamashiro, Tânia T, Takao, Estela C, Ritter, Edgar G, Rizzatti
Publikováno v:
Cytometry. Part B, Clinical cytometry. 86(2)
Background: Multiparameter flow cytometry is a useful tool for the diagnostic evaluation of mature B-cell neoplasms (MBN). Recently, it has been shown that CD200 may improve the distinction between chronic lymphocytic leukemia (CLL; CD200+) and mantl
Autor:
Clifton C. Mo, Arthur L. Shaffer, Patricia Pérez-Galán, Poching Liu, Constance M. Yuan, Marc A. Weniger, Nalini Raghavachari, Colby M. Chapman, Kieron Dunleavy, Maryalice Stetler-Stevenson, Louis M. Staudt, Helena Mora-Jensen, Christoph Rader, Irina Maric, Wyndham H. Wilson, Lawrence S. Stennett, Adrian Wiestner, Stefania Pittaluga, Edgar G. Rizzatti
Bortezomib induces remissions in 30%-50% of patients with relapsed mantle cell lymphoma (MCL). Conversely, more than half of patients' tumors are intrinsically resistant to bortezomib. The molecular mechanism of resistance has not been defined. We ge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa456f5bced2509e213cdf3666121483
https://europepmc.org/articles/PMC3031479/
https://europepmc.org/articles/PMC3031479/
Autor:
Flávia Leite Souza, Santos, Adriana I, Dore, Ana Sílvia G, Lima, Aglair B, Garcia, Marco A, Zago, Edgar G, Rizzatti, Jorge, Elias, Roberto Passetto, Falcão, Eduardo Magalhães, Rego
Publikováno v:
Revista da Associacao Medica Brasileira (1992). 50(3)
Acute Promyelocytic Leukemia (APL) is characterized by its good response to treatment with all trans retinoic acid (ATRA). However, some patients receiving ATRA develop a serious complication called retinoid syndrome (RS). The objective of this study
Autor:
Edgar G, Rizzatti, Fernando L, Portieres, Sérgio L R, Martins, Eduardo M, Rego, Marco A, Zago, Roberto P, Falcão
Publikováno v:
American journal of hematology. 76(1)
Acute promyelocytic leukemia (APL) is a subtype acute myeloid leukemia in which leukemic promyelocytes predominate in the bone marrow (BM). Rapid diagnosis is critical for treatment decision since all-trans-retinoic acid must be administrated promptl